HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baur-Melnyk, A. Articles by Reiser, M. F. Search for Related Content PubMed PubMed Citation Articles by Baur-Melnyk, A. Articles by Reiser, M. F. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

Whole-Body MRI Versus Whole-Body MDCT for Staging of Multiple Myeloma

¹ Institute of Clinical Radiology, University Hospital Grosshadern, Ludwig–Maximilian–University Munich, Marchioninistrasse 15, 81377 Munich, Germany.
² Department of Haemato-Oncology, University Hospital Grosshadern, Ludwig–Maximilian–University Munich, Munich, Germany.

OBJECTIVE. The purpose of our study was to compare the detection rate of bone manifestations of multiple myeloma in whole-body MRI compared with MDCT and to assess accuracy in staging.

SUBJECTS AND METHODS. Forty-one patients with histologically confirmed myeloma were prospectively examined with a whole-body MDCT protocol and whole-body MRI on a 1.5-T system. The MRI protocol consisted of T1-weighted spin-echo and STIR sequences. For data analysis, the entire skeleton was divided into 61 regions per patient. Image evaluation was performed in a consensus reading by two radiologists blinded to the patients' history, with separate evaluation of each technique. The patients were staged by MRI and MDCT data separately according to the Durie and Salmon PLUS staging system.

RESULTS. On MRI, 15 patients showed no involvement. In 26 patients, 975 regions were affected: 21 patients were stage I, two were stage II, and 18 were stage III. On MDCT, 19 patients showed no involvement. In 22 patients, 462 regions were affected. For the detection rate, MRI was statistically superior to MDCT (p < 0.001, Wilcoxon's signed rank test). According to MDCT, 25 patients were stage I, seven were stage II, and nine were stage III. In 21 patients with involvement detected on both methods, MRI showed more extensive disease than MDCT. Eleven patients were understaged with MDCT compared with MRI, which was statistically significant (p < 0.001, chi-square test).

CONCLUSION. Whole-body MDCT leads to a significantly lower detection rate and staging in patients with multiple myeloma.

Keywords: bone marrow • MDCT • MRI • multiple myeloma • whole-body imaging

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Bauerle, J. Hillengass, K. Fechtner, C. M. Zechmann, L. Grenacher, T. M. Moehler, H. Christiane, W.-G. Barbara, K. Neben, H.-U. Kauczor, et al. Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Importance of Whole-Body versus Spinal MR Imaging Radiology, August 1, 2009; 252(2): 477 - 485. [Abstract] [Full Text] [PDF]

				C. Lin, A. Luciani, K. Belhadj, P. Maison, A. Vignaud, J.-F. Deux, P. Zerbib, F. Pigneur, E. Itti, H. Kobeiter, et al. Patients with Plasma Cell Disorders Examined at Whole-Body Dynamic Contrast-enhanced MR Imaging: Initial Experience Radiology, March 1, 2009; 250(3): 905 - 915. [Abstract] [Full Text] [PDF]